During development of iron chelators for the treatment of iron overload in Cooley's anemia, the opportunity arose to obtain some acute and subacute toxicity data on hydroxybenzyl-ethylenediamine (HBED) derivatives, hydroxyphenyl-ethylenediamine (HPED) congeners, and ethylenediamine-phenylacetic acid (EDHPA) compounds. Such data permitted correlations among structure, toxicity, and efficacy parameters useful for further syntheses. Young, adult male mice were used to perform acute intraperitoneal (IP) or oral (PO) LD,, studies, and hypertransfused groups were treated IP or PO with vehicle, Desferal, or test chelators once daily for 7 days. Changes in behavior, weights of spleen, liver, and feces, and urine volume and gross pathology were monitored. In the HBED series, esterification of acetic acid groups with or without acetylation of phenolic hydroxyl groups increased LDSo values, and the major behavioral change was decreased exploratory activity. Dimethylenephosphonate derivatives of HBED were more toxic. Single treatment with compounds in the EDHPA and HPED series yielded IP LD,, values between 175 and 325 mg/kg. After subacute treatment, active compounds were found in each series, and efficacy was related to toxicity. Chelation effectiveness was usually greater by the IP route than orally. The major toxic signs were reduction in organ weights and excreta output.
The ideal chelator should have great specificity for iron and reversible, minimal toxicity. In vitro binding tests can provide affinity data for ligands and metals but are deficient in revealing potential toxicity in the whole animal.
Toxicological information has accumulated as various chelators were applied in the treatment of metal intoxication. The concomitant removal of essential endogenous metals by exogenous ligands ligands with affinity for ferric iron are provided in this article. In addition, gross toxic signs in mice apparent after a 7-day treatment course are described. The chemistry and biological effectiveness of these iron chelators have been published. (2.3. 51 The preliminary toxicity data presented herein may aid others in using these ligands in studying various metals complexes and in pointing direction for synthesis of less toxic related ligands.
MATERIALS AND METHODS
BDF, male mice (Simonsen Laboratories, Gilroy, CA, or Charles River Breeding Laboratories, Kingston, NY) weighing 18-26 g were randomized into quarantined groups of 4-6 animals housed in polycarbonate cages 36 x 30 x 18 cm. Commercial pellet feed (Wayne Blox, Framingham, MA) and tap water were freely available. Acute and subacute studies were in the same room with an ambient temperature of 23 * 2"C, relative humidity of 45-65%, and regulated for a 12-h light-dark cycle and 12 air changes per hour.
In general, a pilot study was used to determine dose range. Thereafter, four to five doses between 25 and 2400 mg/kg were injected once IP or gWaged orally (PO) to estimate LD50 in mice observed for 7 days and necropsied on day 8. The LDso was calculated by the Weil method.(2z) Where compound limitation existed, only a large nonlethal dose could be obtained. Major behavioral changes and some gross pathology were monitored. For subacute studies, there were 10 mice per metabolism cage so that urine and fecal specimens could be collected. The bioassay details of the treatment and asesssment of iron chelation efficacy have been reported.(3 5 . 6 ) Briefly, BDF, male mice were transfused three times with heated canine red blood cells the week before treatment. Test compounds were administered IP or orally with a presumably nonlethal single dose each day for 7 days, and necropsy was performed on the eighth day. Daily behavioral changes as well as alterations in body, liver, spleen, and excreta weights at necropsy were compared with similar parameters in two control groups, one hypertransfused and the other nontransfused.
No statistical methodology was applied, since one dose was used for each compound. Instead the percentage change and direction for each parameter measured on a test compound was compared with mean corresponding data accumulated on control mice from the 20 bioassays used for evaluating the test chelators being studied. When a difference between test compound and control existed, it was considered significant if the percentage change exceeded the coefficient of variation (SD i mean x 100) of a specific parameter. Confirmation of the reliability of such a mathematical paradigm was obtained by similarly calculating the coefficients of variation for the response of the clinically used deferioxamine (Desferal, DF, which was used as an internal standard in each of the 20 bioassays under review. Measurements on organs and excreta were in good agreement for DF and transfused controls, as were the coefficients of variation of both groups.
RESULTS
It is reiterated that a number of these potentially useful iron chelators were in short supply, which precluded estimation of a precise LD,, for every compound. However, the details of synthesis for each compound are available for others to extend investigations on the In regard to the subacute studies, when sufficient compound was available, responses obtained by the IP route were compared with those expressed by the oral route of administration. In this manner, the effect of a first liver pass on toxicity could be assessed. Regarding the significance of percentage changes of each parameter, comparison was made with respective coefficients of variation of pooled data on transfused controls: 7% for body weight, 12% for spleen weight, 10% for liver weight, 20% for fecal weight, and 18% for urine volume. Corresponding coefficients for DF response were 6%, 13%, 8%, 18%, and 17%, respectively.
Toxicity of HBED derivatives
Acute findings are shown in Table 1 . Since precise origins of behavioral changes were not determined., it was assumed that depression (decrease in voluntary activity) was related to central nervous system (CNS) inhibition or general debilitation or a combination of both. "Delayed deaths" indicate that demise of mice occurred in the latter half of treatment in subacute studies. Convulsions were clonic in nature.
HBED 2 HCl, the simplest structure in the series, affected respiration and voluntary exploratory activity. Exogenously synthesized ferric HBED complex had a similar LD,, to that of HBED. 2 HCl but did elicit comparable behavioral alterations. Ferric HBED produced splenomegaly, a slight increase in hepatic size, and excreta specimens were stained red.
Esterification of the diacetic acid groups of HBED diminished acute toxicity. The dimethyl and diethyll esters evoked delayed deaths in contrast to the absence of deaths after diisopropyl ester doses up to 1200 mg/kg. Further elongation of the ester chain (butyl and pentyl derivatives) restored gross behavioral changes at 300-400 mg/kg. Extending the ethylene unit to a propylene unit
suggested a decrease in toxicity, since the LD,, was quite large. HBED, dibenzyl ester was tested orally because that was the primary proposed clinical route for this compound. Toxicity was reduced compared with esters given IP, but CNS inhibition was apparent, since mice had difficulty in coordinating rearing postures.
Acetylation of phenolic hydroxy groups (HBED, diacetyl, dimethyl ester; HBED, diacetyl, ditert-butyl ester; HBPD, diacetyl, dipentyl ester) did not appear to exacerbate toxic signs.
Substitution of the carboxylic acid groups with phosphonic acid groups increased toxicity, as reflected in more intense behavioral changes. The dimethyl and diethyl derivatives of HBED and dimethylenephosphonic acid had larger LD,, values than the mother compound. In contrast, the tetraethyl congener had a smaller LD,, value and more severe behavioral derangements. Only the mother structure impaired excreta production and induced enteritis. None of the compounds altered the appearance of spleen or liver grossly.
A more precise monitoring of gross effects on organs and excreta was achieved in the subacute studies on the HBED series ( Table 2) . Approximately one-half the compounds were tested by two routes of administration at dosages presumed to be nonlethal based on available LD,, data. The reference structure, HBED.2 HCl, given IP reduced body weight 4%, liver weight 2070, fecal weigh1 5070, and urine output 19% (all values corrected for coefficients of variation of controls). When administered orally, HBED.2 HCl also produced decrements; 17% body, 13% liver, and 41% feces declines in weights occurred, as well as a 27% reduction in urine volume. At an oral dose of 200 mg/kg, there were 20% deaths associated with reduced voluntary activity. The responses to ferric HBED given I P were + 3% body, -9% spleen, -4% liver, and + 11 070 fecal weights and +26% urine output. 
TOXICITY OF IRON CHELATORS
The esters of HBED evoked variable changes in organ weights and release of excreta that were related to route of administration. In the majority of instances, oral treatment affected more parameters adversely than did IP treatment. The dimethyl esters and diethyl ester decreased body weight approximately 22%, spleen weight 8-26%, liver weight 23%, fecal weight about SO%, and urine volume approximately 15%. The other ester derivatives generally reduced body, liver, and fecal weights, the latter most noticeably. The dipentyl ester was most active; body, liver, and fecal weight!; were down 21 Yo, 19%, and 42%, respectively. For the diisopropyl ester, ditert-butyl ester, and diacetyldipentyl ester, the decreases in body and liver weights were usually less than 5 % in contrast to a 13-21% decline in fecal output.
Other features of oral treatment included splenic enlargement (19%) by the propylene congener, HBPD-diacetyl, dipentyl ester, minor reduction in the weights of spleen (6Clro) and feces (8%) by HBED-diacetyl, ditert-butyl ester, and lack of response to the dibenzyl ester. An increase in oral dose b y 50 mg/kg for HBED-diacetyl, dimethyl ester and HBED-diethyl ester elicited 50% demises. Similar elevations in oral dosage for both dipentyl esters caused 20-30% deaths related to dyspnea and depression.
The administration of HBED esters IP elicited lesser responses. HBED-diacetyl, dimethyl ester and HBED-ditert-butyl ester increased splenic weight 8% and 27%, respectively. The latter compound also elevated liver weight by 7%. Other esters used IP were inactive.
In the dimethylenephosphonate group, the route of administration as well as dose played a role.
The trisodium salt by both routes had a slight effect on body weight (-4 to -11 Vo) and an identical 13% decrease in fecal weight associated with enteritis. Urine output declined a dramatic 45% only by the IP route. The dimethyl congener was inactive IP, whereas splenic weight fell 5% after oral treatment at a larger dose. The diethyl congener could only be tested IP and was inactive. On the other hand, the tetraethyl relative increased splenic weight 15% at 50 mg/kg IP. Twice the dosage orally did not affect organ weights but decreased fecal weight 15%.
Toxicity of EDHPA and HPED derivatives
Transfer of acetic acid groups from ethylenediamine nitrogen atoms to benzyl carbon atoms yielded derivatives of EDHPA. Acute toxicity data are given in Table 3 . The mother structure and ester analogs evoked depression in the first few days of observation. Assuming the hydrochloride unit did not influence the intensity of toxic signs, administration of the dimethyl ester IP was more deleterious than by the oral route. The assumption was reasonable, since the diethyl ester as the dihydrochloride salt elicited a similar behavioral change to that of the nonhydrochloride salt, both given (orally. Compound limitation prevented attaining more accurate estimates of oral LD,, values. In another study, EDHPA given orally was nonlethal up to dosages of 6000 mg/kg in rodents.
The elimination of the carbon atoms (benzyl) bridge between carbocyclic rings and nitrogen atoms of the ethylenediamine moiety produced the HPED series (Table 3 ). The major behavioral change associated with the three HPED compounds was also depression. Their IP LDso values were of a similar order of magnitude. Of interest was the effect of the dilithium salt on water metabolism. Increased water intake was observed, and a marked elevation in urine output was measured.
The subacute toxicity findings on both the EDHPA and HPED series are enumerated in Table 4 . Nonesterified EDHPA at a low IP dose reduced body, liver, and fecal weights approximately 15-19'70. Despite identical oral doses, the two dimethyl esters did not evoke similar responses for all parameters. The hydrochloride salt decreased organ weights slightly (4-870), whereas the nonsalt form had no effect on organs. However, both structures decreased fecal weight (1 1-13%) and urinary cutput (5-670) nearly the same amount. Body weight fell 3-8% after each compound. Orally administered diethyl ester primarily affected fecal production (+ 17%) and to a much lesser extent body and splenic weights (-3%). The hydrochloride salt of the diethyl ester induced transient depression and no changes in organ weights or excreta output when given IP. In contrast, oral treatment with the nonsalt form at a larger dose had little or no effect on behavior but reduced body NO TO), spleen (5%), liver (lo%), and fecal (14%) weights. The route of administration differentiated the responses of the sodium salt of HPED. Intraperitoneally, HPED.2 Na markedly increased urine volume by 120% in the moderately depressed mice. At twice the IP dose (200 mg/kg), depression was associated with dyspnea and 50% lethality. Generally, organ weights and excreta production were inhibited, although there was a trend to enhanced urine output. At the lower dose of 100 mg/kg given orally, the sodium salt caused slight depression and decreased splenic weight by 16% and liver weight a slight 5%.
HPED, dilithium salt also increased urine volume irrespective of route of treatment. An IP dose of 129 mg/kg induced dyspnea and depression, an 8% decline in body and liver weights, a 21% fall in fecal weight, and 179% increase in urine output. By the oral route, a 200 mg/kg dose evoked slight depression and decreases of 32% and 10Vo for spleen and liver weights, respectively, and urine volume rose 16%.
HPED, dilactone at 170 mg/kg IP had negative effects on all parameters as well as 20% deaths. The decreases in weights (or volume) were 17%, 7%, 16%, 51%, and 31% for body, spleen, liver, fecal, and urinary parameters, respectively. A similar oral dose of the dilactone induced a transient depression, no effects on excreta production, and a decline of 9% and 4% for splenic and liver weights, respectively.
DISCUSS I 0 N
Although the disposition and toxicity of many metals are k n~w n , '~~.~~) both the diversity of biological processes they affect and the paucity of suitable chelators to reverse intoxication are still being in~estigated.'~~) Of course, specificity of detoxification of a particular metal is desirable, and, in the instance of iron, somewhat critical because of the potential interference with the functions of hemoglobin and cytochromes. Clinical syndromes of hemochromatosis or iron overload arising from multiple blood transfusions require that the oxidative state of iron be considered in sequestering arid excreting excessive iron. Ligand formation with ferric ions is less likely to evoke organ dysfunction than ligand-ferrous complexes. (4,26-301 In general, the efficacy and toxicity of EDTA-derived ligands depend on the metal being chelated, the route of administration, and the time interval of treatment. '3.s20.31) These same factors would appear to apply to more complex derivatives of EDTA as represented by the HBED, EDHPA, and HPED series. However, it has been shown that these more complex chelators have substantial affinity for ferric ions. Coirnpounds with an iron chelation effectiveness similar or greater than Desferal include HBED, dimethyl ester; both HBED, diethyl esters; HBED, dipentyl ester; EDHPA; EDHPA, dimethyl ester 0 2 HCI; EDHPA diethyl ester. 2 HCI; HPED 2 Na; HPED, dilithium salt; and HPED, dilactone.'2.3,s1 Efficacy by the oral route was sometimes reduced, and such decrease in effectiveness may be related to oral toxicity of the compound. Among the active iron chelators given orally, the dimethyl, diethyl, and dipentyl esters of HBED generally reduced body, spleen, liver, and fecal weights and urine volume. Retention of efficacy would indicate structural protection by esterification, whereas a subsequent hepatic metabolite and/or formation of an iron-ligand complex or both may have contributed to toxicity. It is possible that &he chelator could have formed a ligand with dietary iron in the intestine, and thus bioavailability may have been reduced. However, the active HBED compounds did not cause red coloration of intestinal fluid or feces, and evidence of enteritis was absent. Ferric HBED itself not surprisingly decreased spleen weight but increased liver weight.
These organs are the major depots of iron and serve as magnets for chelator residence. The compound had more intense effects on urine excretion and might cause nephrotoxicity, as in the instance of Fe * NTA'") and EDHPAIZo1 if treatment were prolonged. No phosphonate derivatives of HBED were effective iron chelators.
ED,HPA and HPED compounds were generally more toxic than the HBED series based on LD,, va1ue:s. EDHPA and its dimethyl and diethyl esters as hydrochloride salts were quite active, moreso IP than orally. (23.5.20m Subacute toxicity also was more prevalent among active EDHPA compounds than HBED compounds. A decrease in fecal output was predominant, and decreases in body and organs weights were common.
The three HPED compounds were active iron chelators, but subacute treatment with them evoked variable responses. Generally, there was a reduction in organ weights. Declines in fecal weighi were associated with the IP route. Whereas all parameters were decreased by HPED, dilactone given IP, similar treatment with HPED 2 Na and HPED, dilithium salt increased urine output. It is known that lithium treatment of patients induces a diabetes insipidus-like condition characterized by polyuria and polydypsia. It seems reasonable that such pharmacological effect might involve the hypophyseal-adrenal axis. That some of the chelators affected fecal production after IP administration suggested a mode of action, centrally or on the intestinal nervous system, possibly disturbing intestinal motility and the compaction process.
The findings of the present studies indicate that certain structural alterations of EDTA improve specificity and efficacy in the treatment of iron intoxication. Acetylation or esterification and enhancement of solubility via salt forms may be beneficial, but a diversity of toxic signs may offset gains in chelation effectiveness. Nevertheless, it seems clear that whole animal assessment of efficacy ,and toxicity cannot be replaced by in vitro measurement of binding constants or monitoring iron distribution in cell cultures in establishing a chelator as a likely clinical candidate.
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